Fosun Pharma

Historical price data

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive pharmaceutical and healthcare conglomerate that has evolved from a Chinese pharmaceutical company into a global innovation leader. The company operates through diversified business segments including pharmaceutical manufacturing, vaccines, medical devices, medical diagnostics, and healthcare services, while also maintaining significant positions in pharmaceutical distribution through its Sinopharm investment. Fosun Pharma has established technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy, with particular focus on first-in-class and best-in-class drug development. The company's commitment to innovation is demonstrated through its substantial R&D expenditure of RMB 5.554 billion in FY2024 and its successful development of globally recognized products like Artesun®, which has treated over 56 million severe malaria patients worldwide.

Fosun Pharma operates comprehensive technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy, while exploring cutting-edge technologies including RNA, oncolytic viruses, gene therapy, and PROTAC.

1 drug in pipeline

Fosun Pharma competes with major Chinese pharmaceutical companies like Jiangsu Hengrui and global pharmaceutical giants across various therapeutic areas. The company differentiates itself through its diversified healthcare ecosystem approach, strong domestic market position, successful global drug development track record with products like Artesun®, and comprehensive platform spanning multiple healthcare verticals from manufacturing to services.